These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 15027457)

  • 21. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 22. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 24. Compulsory licensing of patents in India.
    Chaudhry R
    Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 26. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 27. The case for compulsory licensing during COVID-19.
    Wong H
    J Glob Health; 2020 Jun; 10(1):010358. PubMed ID: 32509289
    [No Abstract]   [Full Text] [Related]  

  • 28. Bundling patented drugs and medical services: an antitrust analysis.
    Hurwitz MA
    Spec Law Dig Health Care Law; 1992 Jan; (155):7-39. PubMed ID: 10115664
    [No Abstract]   [Full Text] [Related]  

  • 29. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 30. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 31. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 34. A license to print money?
    Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
    [No Abstract]   [Full Text] [Related]  

  • 35. Gene patents, health care policy and licensing schemes.
    Caulfield T; von Tigerstrom B
    Trends Biotechnol; 2006 Jun; 24(6):251-4. PubMed ID: 16621074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 37. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
    Manthei JR; Hathaway CR; Grant MA; Chung DD
    Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
    [No Abstract]   [Full Text] [Related]  

  • 38. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 39. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 40. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.